Roche is set to introduce its three next-generation SARS-CoV-2 rapid antigen tests (‘2.0’) for self-test and professional use in countries that accept the CE Mark.
The tests include the SARS-CoV-2 Rapid Antigen Test 2.0, the SARS-CoV-2 Rapid Antigen Test 2.0 Nasal for professional use, and the SARS-CoV-2 Antigen Self Test Nasal for self-test.
They feature improved performance, with the addition of new digital data sharing capabilities and an enhanced capture antibody.
The new SARS-CoV-2 rapid antigen tests (‘2.0’) use nasopharyngeal and nasal swab samples, respectively, and provide results in 15 minutes.
This aids in a SARS-CoV-2 infection diagnosis in people with or without symptoms.
The company stated that all the three tests have the capability to detect major variants of concern, including Delta and Omicron variants.
Roche Diagnostics CEO Thomas Schinecker said: “The continued evolution of the SARS-CoV-2 virus and Covid-19 pandemic reinforce the need for individuals and healthcare systems to have access to the most reliable rapid testing solutions possible.
“As a leader in diagnostic innovation, we are proud to be one of the first among our industry to apply insights gained from the past two years toward a next-generation rapid test portfolio.
“These tests are ready to support global society as we navigate this next phase of the pandemic.”
They join the company’s broad Covid-19 portfolio that includes various serological, molecular, and digital solutions.
These solutions help in diagnosing and managing the disease in the initial stages of infection, during the recovery phase, and after the resolution of infection.
Roche intends to start distribution of the new rapid test portfolio in the coming weeks.